SCHEMBL11945112

SCHEMBL11945112

CCOC(=O)C1CCC(Oc2c(N3CCN(S(=O)(=O)C4CC4)CC3)cnn(-c3ccccc3)c2=O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.48
▸ ALDH1A1 P00352 8/20 0.47
▸ DCTPP1 Q9H773 3/20 0.45
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MAPK8 P45983 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943990 0.91 KMT2A (0.56) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11945109 0.90 MAPT (0.47) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11945114 0.89 NPSR1 (0.58) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11943991 0.87 ALDH1A1 (0.45) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11945107 0.86 ALDH1A1 (0.51) MAPTALDH1A1DCTPP1KMT2ANPSR1
SCHEMBL11944538 0.85 ALDH1A1 (0.51) MAPTALDH1A1DCTPP1KMT2ANPSR1
SCHEMBL11944014 0.84 ALDH1A1 (0.49) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11944011 0.83 NPSR1 (0.52) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11945106 0.82 ALDH1A1 (0.49) MAPTALDH1A1DCTPP1KMT2ANPSR1
SCHEMBL11945091 0.80 MAPT (0.52) MAPTALDH1A1DCTPP1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback